Cyclopharm (ASX:CYC) Stock Based Compensation: A$0.00 Mil (TTM As of Dec. 2025)


ASX:CYC Cyclopharm Ltd ASX:CYC
45 GF Score
Price A$0.48
GF Value A$0.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Stock Based Compensation?

Cyclopharm ASX:CYC -4.04% 45 Stock Based Compensation is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 45/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review.

Cyclopharm's Stock Based Compensation for the six months ended in Dec. 2025 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Cyclopharm Stock Based Compensation Related Terms

Cyclopharm Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Cyclopharm's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm Stock Based Compensation Chart

Cyclopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cyclopharm Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CYC
45GF Score
Cyclopharm Ltd ASX:CYC
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclopharm Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

What does a Stock Based Compensation of A$0.00 Mil mean?
Cyclopharm (ASX:CYC) has a Stock Based Compensation of A$0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cyclopharm and its competitors.
Is Cyclopharm's Stock Based Compensation too high?
Cyclopharm's current Stock Based Compensation is A$0.00 Mil. Overall, Cyclopharm has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Stock Based Compensation compare to MCK and CAH?
Cyclopharm's Stock Based Compensation of A$0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Distribution company?
A good Stock Based Compensation depends on the Medical Distribution industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Cyclopharm and its competitors. Cyclopharm's current Stock Based Compensation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.48 — trading 42.8% below its estimated fair value. The current Stock Based Compensation is A$0.00 Mil. Cyclopharm's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Stock Based Compensation is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.48 is trading 42.8% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • Stock Based Compensation: A$0.00 Mil
  • GF Value™: A$0.83 vs. price of A$0.48 (42.8% below fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score

Get the complete analysis for ASX:CYC

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price
A$0.83
GF Value